Cetalkonium
Small moleculeexperimental
Cetalkonium chloride is a cationic quaternary ammonium surfactant, which is used for the treatment of mouth ulcers and sores (Bonjela trade name). It is also serves as an excipient for the purpose of long-term stabilization of ciclosporin ocular formulation, used in patients with dry eye syndrom (Ikervis trade name). The antibacterial properties of cetalkonium can be explained by its detergent character. Once applied, cetalkonium blocks the survival of biofilm forming bacterias. — NCATS
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 12, 2018 (NCT03833570)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified target
positive charge
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1- Mol. weight
- 360.6394 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCetalkonium chloride ↗
- NCATSFHG725432Z ↗
- ChEMBLCHEMBL1624075 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04308161 | Phase 2 | Nov 2, 2019 | Alexandria University |
| NCT04317183 | Phase 2 | May 15, 2019 | Alexandria University |
| NCT03833570 | Phase 2 | Jan 12, 2018 | Alexandria University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexandria University | Academic/Hospital | 3 | 3 | 1 | 2018 |
1 organizations
Page 1 / 1